Elisabetta Antonioli
YOU?
Author Swipe
View article: Correction to: Continous or fixed carfilzomib, lenalidomide and dexamethasone (KRD) for relapsed-refractory multiple myeloma: long-term follow-up from a multicenter, retrospective real-life survey from European myeloma network (EMN) Italy
Correction to: Continous or fixed carfilzomib, lenalidomide and dexamethasone (KRD) for relapsed-refractory multiple myeloma: long-term follow-up from a multicenter, retrospective real-life survey from European myeloma network (EMN) Italy Open
View article: The treatment of patients primary refractory or with sub-optimal response to d-VTD induction: An italian real-life Study
The treatment of patients primary refractory or with sub-optimal response to d-VTD induction: An italian real-life Study Open
Despite the improvement in the treatment of multiple myeloma (MM) patients, there is still a consistent fraction of patients who have a primary refractory MM (PRMM) or relapse early during treatment. Up to now in Italy the treatment for ne…
View article: Continous or fixedcarfilzomib, lenalidomide and dexamethasone (krd) for relapsed-refractory multiple myeloma: long-term follow-up from a multicenter, retrospective real-life surveyfrom European myeloma network (emn) Italy
Continous or fixedcarfilzomib, lenalidomide and dexamethasone (krd) for relapsed-refractory multiple myeloma: long-term follow-up from a multicenter, retrospective real-life surveyfrom European myeloma network (emn) Italy Open
View article: Bortezomib-melphalan-prednisone versus lenalidomide-dexamethasone in elderly patients with multiple myeloma: the Real MM phase IV trial
Bortezomib-melphalan-prednisone versus lenalidomide-dexamethasone in elderly patients with multiple myeloma: the Real MM phase IV trial Open
Not available.
View article: Combined Minimal Residual Disease Evaluation in Bone Marrow and Apheresis Samples in Multiple Myeloma Patients Undergoing Autologous Stem Cell Transplantation Improves Outcome Prediction
Combined Minimal Residual Disease Evaluation in Bone Marrow and Apheresis Samples in Multiple Myeloma Patients Undergoing Autologous Stem Cell Transplantation Improves Outcome Prediction Open
Introduction: Despite the approval of novel agents that have significantly improved long-term survival rates for multiple myeloma (MM) patients undergoing autologous stem cell transplant (ASCT), most patients eventually relapse. The failur…
View article: Revised renal stratification and progression models for predicting long-term renal outcomes in immunoglobulin light chain amyloidosis
Revised renal stratification and progression models for predicting long-term renal outcomes in immunoglobulin light chain amyloidosis Open
Renal prognosis in light-chain amyloidosis (AL) is determined by categorizing patients into three renal stages at diagnosis and assessing Renal Response or Renal Progression following chemotherapy after 6 months. We evaluated, in a test (N…
View article: Lenalidomide maintenance after bortezomib, thalidomide and dexamethasone (VTD) induction and autologous stem cell transplantation: an Italian real-life study of 602 patients
Lenalidomide maintenance after bortezomib, thalidomide and dexamethasone (VTD) induction and autologous stem cell transplantation: an Italian real-life study of 602 patients Open
Not available.
View article: Clinicians’ Perspectives and Methodological Application of Fluorescence in situ Hybridization (FISH) to Define Cytogenetic Risk in Multiple Myeloma: An Italian, Real-World, Survey-Based Report From the European Myeloma Network (EMN) Italy
Clinicians’ Perspectives and Methodological Application of Fluorescence in situ Hybridization (FISH) to Define Cytogenetic Risk in Multiple Myeloma: An Italian, Real-World, Survey-Based Report From the European Myeloma Network (EMN) Italy Open
View article: Prognostic Significance of +1q Alterations in Relapsed/Refractory Multiple Myeloma Treated With Daratumumab‐, Elotuzumab‐, and Carfilzomib‐Based Triplet Regimens: A Multicenter Real‐World Analysis of 635 Patients
Prognostic Significance of +1q Alterations in Relapsed/Refractory Multiple Myeloma Treated With Daratumumab‐, Elotuzumab‐, and Carfilzomib‐Based Triplet Regimens: A Multicenter Real‐World Analysis of 635 Patients Open
Relapsed/refractory multiple myeloma (RRMM) research on the impact of +1q abnormalities in real‐world settings is limited. This study evaluated the prognostic and predictive significance of 1q gain [gain(1q)] and amplification [ampl(1q)] i…
View article: Comparison of isatuximab-pomalidomide-dexamethasone <i>versus</i> elotuzumab-pomalidomidedexamethasone in relapsed/refractory multiple myeloma patients: a target trial emulation using real-world data
Comparison of isatuximab-pomalidomide-dexamethasone <i>versus</i> elotuzumab-pomalidomidedexamethasone in relapsed/refractory multiple myeloma patients: a target trial emulation using real-world data Open
Not available.
View article: Isatuximab, pomalidomide, and dexamethasone as salvage therapy for patients with multiple myeloma: the Italian, multicenter, retrospective clinical experience with 270 cases outside of controlled clinical trials
Isatuximab, pomalidomide, and dexamethasone as salvage therapy for patients with multiple myeloma: the Italian, multicenter, retrospective clinical experience with 270 cases outside of controlled clinical trials Open
Not available.
View article: Clinical Presentation and Long‐Term Survival Outcomes of Patients With Monoclonal Gammopathy of Renal Significance (MGRS): A Multicenter Retrospective Study
Clinical Presentation and Long‐Term Survival Outcomes of Patients With Monoclonal Gammopathy of Renal Significance (MGRS): A Multicenter Retrospective Study Open
Introduction MGRS are new rare clinical entities, whose recognition and optimal management is evolving. Methods To implement real‐life data, we retrospectively analysed a multicentre cohort of 60 patients with renal biopsy‐proven MGRS rece…
View article: Carfilzomib‐Induced Thrombotic Microangiopathy—Two Case Reports
Carfilzomib‐Induced Thrombotic Microangiopathy—Two Case Reports Open
Background Thrombotic microangiopathy (TMA) is a pathological syndrome characterized by a combination of three key features: microangiopathic hemolytic anemia (MAHA), thrombocytopenia, and organ damage, primarily affecting the kidneys. The…
View article: A plain language summary of the PERSEUS study of daratumumab plus bortezomib, lenalidomide, and dexamethasone for treating newly diagnosed multiple myeloma
A plain language summary of the PERSEUS study of daratumumab plus bortezomib, lenalidomide, and dexamethasone for treating newly diagnosed multiple myeloma Open
The results of the PERSEUS study showed that including daratumumab in D-VRd induction/consolidation and D-R maintenance was better for treating multiple myeloma than the current standard VRd treatment followed by R maintenance alone in adu…
View article: Anti-BCMA CAR-T cell-based therapies and bispecific antibodies in the immunotherapy era: are we ready for this?
Anti-BCMA CAR-T cell-based therapies and bispecific antibodies in the immunotherapy era: are we ready for this? Open
CAR-T and BsAbs anti-BCMA strategies represent breakthrough therapies against MM. However, their inclusion in clinical practice is almost feared, due to the associated limitations, some of which have been addressed here. Meanwhile, all the…
View article: Belantamab mafodotin in triple‐refractory multiple myeloma patients: A retro‐prospective observational study in Italy
Belantamab mafodotin in triple‐refractory multiple myeloma patients: A retro‐prospective observational study in Italy Open
Belantamab mafodotin is the first‐in‐class antibody‐drug conjugates targeting B‐cell maturation antigen to have demonstrated effectiveness in triple‐class refractory multiple myeloma (TCR‐MM) patients. We performed a retrospective study in…
View article: Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone for Multiple Myeloma
Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone for Multiple Myeloma Open
The addition of subcutaneous daratumumab to VRd induction and consolidation therapy and to lenalidomide maintenance therapy conferred a significant benefit with respect to progression-free survival among transplantation-eligible patients w…
View article: Phase 3 Randomized Study of Daratumumab (DARA) + Bortezomib, Lenalidomide, and Dexamethasone (VRd) Versus Vrd Alone in Patients (Pts) with Newly Diagnosed Multiple Myeloma (NDMM) Who Are Eligible for Autologous Stem Cell Transplantation (ASCT): Primary Results of the Perseus Trial
Phase 3 Randomized Study of Daratumumab (DARA) + Bortezomib, Lenalidomide, and Dexamethasone (VRd) Versus Vrd Alone in Patients (Pts) with Newly Diagnosed Multiple Myeloma (NDMM) Who Are Eligible for Autologous Stem Cell Transplantation (ASCT): Primary Results of the Perseus Trial Open
Introduction: DARA plus bortezomib, thalidomide, and dexamethasone (D-VTd) quadruplet therapy has shown clinical benefit versus VTd alone and is approved for transplant-eligible pts with NDMM. VRd induction followed by autologous stem cell…
View article: P1680: HEALTH-RELATED QUALITY OF LIFE IN TRANSPLANT-INELIGIBLE REAL-LIFE MULTIPLE MYELOMA PATIENTS TREATED WITH FIXED-DURATION BORTEZOMIB-MELPHALAN-PREDNISONE VS. CONTINUOUS LENALIDOMIDE-DEXAMETHASONE
P1680: HEALTH-RELATED QUALITY OF LIFE IN TRANSPLANT-INELIGIBLE REAL-LIFE MULTIPLE MYELOMA PATIENTS TREATED WITH FIXED-DURATION BORTEZOMIB-MELPHALAN-PREDNISONE VS. CONTINUOUS LENALIDOMIDE-DEXAMETHASONE Open
Topic: 35. Quality of life and palliative care Background: Multiple myeloma (MM) is a chronic disease, and fixed-duration therapies to treat it are rare. The impact of continuous treatment on health-related quality of life (HRQoL) may be b…
View article: P17 CLONAL PLASMA-CELLS IN STEM CELL APHERESIS AS A PREDICTOR OF PROGRESSION IN NEWLY DIAGNOSED MULTIPLE MYELOMA PATIENTS ELEGIBLE FOR AUTOLOGOUS STEM CELL TRANSPLANTATION
P17 CLONAL PLASMA-CELLS IN STEM CELL APHERESIS AS A PREDICTOR OF PROGRESSION IN NEWLY DIAGNOSED MULTIPLE MYELOMA PATIENTS ELEGIBLE FOR AUTOLOGOUS STEM CELL TRANSPLANTATION Open
Background: Flow-cytometry is considered crucial for monitoring multiple myeloma (MM) patients, in particularly for evaluation of minimal residual disease (MRD) [1]. Routinely MRD on bone marrow aspirate is the optimal method for assessing…
View article: P22 THE PROGNOSTIC ROLE OF 1Q ABNORMALITIES IN NEWLY DIAGNOSED MULTIPLE MYELOMA PATIENTS
P22 THE PROGNOSTIC ROLE OF 1Q ABNORMALITIES IN NEWLY DIAGNOSED MULTIPLE MYELOMA PATIENTS Open
Background: Additional copies of chromosome 1q (+1q) is one of the most common cytogenetic abnormalities in multiple myeloma, with a frequency in newly diagnosed patients (NDMM) around 30-50%. However, its prognostic impact is still debate…
View article: P07 BORTEZOMIB-MELPHALAN-PREDNISONE (VMP) VS. LENALIDOMIDE-DEXAMETHASONE (RD) IN REAL-LIFE MULTIPLE MYELOMA PATIENTS INELIGIBLE FOR TRANSPLANT: UPDATED ANALYSIS OF THE RANDOMIZED PHASE IV REAL MM TRIAL
P07 BORTEZOMIB-MELPHALAN-PREDNISONE (VMP) VS. LENALIDOMIDE-DEXAMETHASONE (RD) IN REAL-LIFE MULTIPLE MYELOMA PATIENTS INELIGIBLE FOR TRANSPLANT: UPDATED ANALYSIS OF THE RANDOMIZED PHASE IV REAL MM TRIAL Open
Background: Until the recent introduction of daratumumab (Dara), bortezomib-melphalan-prednisone (VMP) and lenalidomide-dexamethasone (Rd) have been standards of care for transplant-ineligible (NTE) newly diagnosed multiple myeloma (NDMM) …
View article: P20 LENALIDOMIDE MAINTENANCE AFTER VTD INDUCTION AND AUTOLOGOUS STEM CELL TRANSPLANTATION: PRELIMINARY RESULTS OF A REAL-LIFE STUDY INCLUDING 389 PATIENTS
P20 LENALIDOMIDE MAINTENANCE AFTER VTD INDUCTION AND AUTOLOGOUS STEM CELL TRANSPLANTATION: PRELIMINARY RESULTS OF A REAL-LIFE STUDY INCLUDING 389 PATIENTS Open
According to 2021 ESMO guidelines, treatment of newly diagnosed (ND) transplant eligible (TE) Multiple Myeloma (MM) patients is settled by an induction phase followed by single or tandem autologous stem cell transplantation (ASCT) and Lena…
View article: P48 CARFILZOMIB, LENALIDOMIDE AND DEXAMETHASONE IN RELAPSED REFRACTORY MULTIPLE MYELOMA: A PROSPECTIVE REAL-LIFE EXPERIENCE OF THE REGIONAL TUSCAN MYELOMA NETWORK (RTM)
P48 CARFILZOMIB, LENALIDOMIDE AND DEXAMETHASONE IN RELAPSED REFRACTORY MULTIPLE MYELOMA: A PROSPECTIVE REAL-LIFE EXPERIENCE OF THE REGIONAL TUSCAN MYELOMA NETWORK (RTM) Open
Background: In recent years, the clinical outcome of multiple myeloma (MM) patients has improved due to the introduction of several new agents, such as the third-generation immunomodulator, the next-generation proteasome inhibitors (PIs) a…
View article: Carfilzomib, lenalidomide, and dexamethasone in relapsed refractory multiple myeloma: a prospective real-life experience of the Regional Tuscan Myeloma Network
Carfilzomib, lenalidomide, and dexamethasone in relapsed refractory multiple myeloma: a prospective real-life experience of the Regional Tuscan Myeloma Network Open
Introduction Carfilzomib, a potent, irreversible, selective proteasome inhibitor has demonstrated consistent results in relapsed/refractory multiple myeloma (RRMM) combined with lenalidomide and dexamethasone (KRd). No prospective studies …
View article: A multidisciplinary case report of multiple myeloma with renal and cardiac involvement: a look beyond amyloidosis
A multidisciplinary case report of multiple myeloma with renal and cardiac involvement: a look beyond amyloidosis Open
View article: Case report: Unexpected parvovirus B19 infection in a myeloma patient treated with daratumumab
Case report: Unexpected parvovirus B19 infection in a myeloma patient treated with daratumumab Open
Multiple myeloma patients have an increased risk of infections due to both the inherent nature of the disease and ongoing treatment. We describe the case of a patient who was treated with daratumumab-lenalidomide-dexamethasone regimen for …
View article: Association of IMWG frailty score with health-related quality of life profile of patients with relapsed refractory multiple myeloma in Italy and the UK: a GIMEMA, multicentre, cross-sectional study
Association of IMWG frailty score with health-related quality of life profile of patients with relapsed refractory multiple myeloma in Italy and the UK: a GIMEMA, multicentre, cross-sectional study Open
View article: Carfilzomib plus dexamethasone in patients with relapsed and refractory multiple myeloma: A retro‐prospective observational study
Carfilzomib plus dexamethasone in patients with relapsed and refractory multiple myeloma: A retro‐prospective observational study Open
Objective We investigate safety and efficacy in common clinical practice of the combination of carfilzomib and dexamethasone (Kd56) approved for the ENDEAVOR trial for the treatment of relapsed or refractory multiple myeloma. Methods We re…
View article: PB1984: ELOTUZUMAB PLUS LENALIDOMIDE AND DEXAMETHASONE IN RELAPSED/REFRACTORY MULTIPLE MYELOMA: EXTENDED 3-YEAR FOLLOW-UP OF AN ITALIAN, MULTICENTER, EXPERIENCE OUTSIDE OF CONTROLLED CLINICAL TRIALS
PB1984: ELOTUZUMAB PLUS LENALIDOMIDE AND DEXAMETHASONE IN RELAPSED/REFRACTORY MULTIPLE MYELOMA: EXTENDED 3-YEAR FOLLOW-UP OF AN ITALIAN, MULTICENTER, EXPERIENCE OUTSIDE OF CONTROLLED CLINICAL TRIALS Open
Background: The combination of elotuzumab, lenalidomide, and dexamethasone (EloRd) enhanced the clinical benefit over Rd with a manageable toxicity profile in the ELOQUENT-2 trial, leading to its approval in relapsed/refractory multiple my…